Cannabis use disorder: Clinical features and diagnosis
- Robert L DuPont, MD
Robert L DuPont, MD
- Clinical Professor of Psychiatry
- Georgetown University School of Medicine
- John A Bailey, MD
John A Bailey, MD
- Clinical Assistant Professor of Psychiatry
- University of Florida
- Scott A Teitelbaum, MD
Scott A Teitelbaum, MD
- Professor of Psychiatry
- University of Florida
Cannabis is the most commonly used illegal substance worldwide . Approximately 160 million people, or approximately four percent of the world’s population between the ages of 15 and 64 years, have been estimated to use cannabis at least once in the past year.
The psychoactive properties of cannabis are primarily due to delta-9-tetrahydrocannabinol (THC) . The THC content of marijuana has increased significantly since the late 1960s from approximately 1 to 5 percent to as much as 10 to 15 percent . This increased potency may contribute to increased rates of cannabis use disorder.
The psychiatric diagnoses, cannabis abuse and cannabis dependence, in DSM-IV-TR were replaced by one diagnosis, cannabis use disorder, in DSM-5 .
The clinical features and diagnosis of cannabis use disorder in adults are reviewed here. Other issues related to cannabis use disorder are discussed separately. Acute cannabis intoxication is also discussed separately. Treatment of medical conditions such as chemotherapy-induced emesis and cancer pain with cannabinoids are discussed separately. (See "Cannabis use disorder: Epidemiology, comorbidity, and pathogenesis" and "Substance use disorder: Principles for recognition and assessment in general medical care" and "Cannabis use disorder: Treatment, prognosis, and long-term medical effects" and "Cannabis (marijuana): Acute intoxication".)
Intoxication — The clinical presentation of cannabis intoxication is described separately. (See "Cannabis (marijuana): Acute intoxication" and "Cannabis (marijuana): Acute intoxication", section on 'Clinical manifestations'.)
- Leggett T, United Nations Office on Drugs and Crime. A review of the world cannabis situation. Bull Narc 2006; 58:1.
- Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178:101.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington DC 2000.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
- Nocon A, Wittchen HU, Pfister H, et al. Dependence symptoms in young cannabis users? A prospective epidemiological study. J Psychiatr Res 2006; 40:394.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 2000.
- von Sydow K, Lieb R, Pfister H, et al. The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. Drug Alcohol Depend 2001; 64:347.
- Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 2002; 26:479.
- Degenhardt L, Chiu WT, Sampson N, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med 2008; 5:e141.
- World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007. http://www.who.int/classifications/apps/icd/icd10online/ (Accessed on September 2, 2009).
- Hasin DS, Keyes KM, Alderson D, et al. Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry 2008; 69:1354.
- Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161:1967.
- Mennes CE, Ben Abdallah A, Cottler LB. The reliability of self-reported cannabis abuse, dependence and withdrawal symptoms: multisite study of differences between general population and treatment groups. Addict Behav 2009; 34:223.
- Gavin DR, Ross HE, Skinner HA. Diagnostic validity of the drug abuse screening test in the assessment of DSM-III drug disorders. Br J Addict 1989; 84:301.
- Swift W, Copeland J, Hall W. Choosing a diagnostic cut-off for cannabis dependence. Addiction 1998; 93:1681.
- Kleber HD, Weiss RD, Anton RF Jr, et al. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry 2007; 164:5.
- DuPont, RL, Selavka, CM. Testing to identify recent drug use. In: The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th ed, Galanter, M, Kleber HD (Eds), American Psychiatric Publishing, Washington, DC 2008. p.655.
- ElSohly MA, deWit H, Wachtel SR, et al. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol 2001; 25:565.